Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #70240 on Anavex Life Sciences Corp (AVXL)
howcanitell
07/27/16 8:11 AM
#70243 RE: BostonSportsNut #70240
TomP1
07/27/16 8:14 AM
#70245 RE: BostonSportsNut #70240
While the TRx-237-015 study in 891 subjects failed to meet its co-primary endpoints, clinically meaningful and statistically significant reductions in the rate of disease progression were observed across three key measures in patients who were treated with LMTX® as their only Alzheimer’s disease medication. These three key measures comprised a cognitive assessment (ADAS-Cog), a functional assessment (ADCS-ADL) and an assessment of the level of brain atrophy (lateral ventricular volume, LVV, as measured by MRI).
Study TRx-237-015, was a randomised double-blind placebo-controlled study in 891 subjects
FooBarAndGrill
07/27/16 11:08 AM
#70288 RE: BostonSportsNut #70240